X‑linked Dystrophinopathy (Duchenne/Becker Muscular Dystrophy)

Overview

X‑linked dystrophinopathy refers to a spectrum of muscle‑wasting disorders caused by mutations in the DMD gene, which encodes the protein dystrophin. The two most common phenotypes are:

• Duchenne Muscular Dystrophy (DMD) – severe, early‑onset form.
• Becker Muscular Dystrophy (BMD) – milder, later‑onset form.

Both are inherited in an X‑linked recessive pattern, meaning the defective gene is located on the X chromosome. Boys who inherit the mutated gene develop the disease; females are usually carriers, though ~2‑10 % may have mild symptoms.

Prevalence: Worldwide, DMD affects approximately 1 in 3,500–5,000 male births, while BMD occurs in about 1 in 18,000–20,000 male births [1][2]. The combined prevalence is therefore roughly 1 in 3,500 male live births.

Symptoms

Symptoms progress in a predictable pattern, but the exact onset and severity differ between DMD and BMD.

Early childhood (typically 2‑5 years)

• Motor delays: Trouble sitting, crawling, or walking.
• Gower’s sign: Using hands to “climb” up the legs to stand.
• Calf pseudohypertrophy: Enlarged calves due to fatty infiltration.
• Frequent falls and difficulty running or jumping.

School‑age (5‑12 years)

• Progressive weakness of proximal muscles (hips, shoulders).
• Waddling gait and toe‑walking.
• Joint contractures, especially at the ankles and knees.
• Developing scoliosis.

Adolescence to early adulthood

• Duchenne: Loss of ambulation usually between ages 10‑13.
• Becker: May retain walking ability into the 30s or 40s.
• Cardiac involvement – dilated cardiomyopathy, arrhythmias.
• Respiratory muscle weakness leading to reduced vital capacity.
• Fatigue, difficulty with fine motor tasks (writing, buttoning).

Other possible features

• Learning disabilities or attention‑deficit/hyperactivity disorder (more common in DMD).
• Gastrointestinal issues (constipation, reflux).
• Bone health problems – osteoporosis, increased fracture risk.

Causes and Risk Factors

The root cause is a mutation in the DMD gene located at Xp21.2. The gene is one of the largest in the human genome (≈2.4 Mb) and is prone to deletions, duplications, or point mutations.

• Types of mutations
  • Deletions (≈65 % of cases) – loss of one or more exons.
  • Duplications (≈10 %).
  • Point mutations (nonsense, splice‑site, missense) – the remainder.
• Frameshift vs. In‑frame – If the mutation disrupts the reading frame (frameshift), dystrophin is absent → Duchenne phenotype. If the reading frame is preserved (in‑frame), a shortened but partially functional protein is produced → Becker phenotype.

Who is at risk?

• Male infants born to a carrier mother (≈50 % chance per pregnancy).
• Rarely, a new (de novo) mutation can occur; about one‑third of cases arise without a known carrier.
• Female carriers have a low risk of manifesting symptoms, but may develop cardiomyopathy later in life.

Diagnosis

Early diagnosis is crucial for initiating therapy and family counseling.

Clinical evaluation

• Detailed developmental and family history.
• Physical exam focusing on Gower’s sign, calf pseudohypertrophy, and contractures.
• CK (creatine kinase) level – often >10‑fold normal in early disease.

Laboratory & genetic testing

1. Creatine kinase (CK) test – highly sensitive but not specific.
2. Molecular genetic testing – multiplex ligation‑dependent probe amplification (MLPA) for deletions/duplications; next‑generation sequencing (NGS) for point mutations.
3. Dystrophin protein analysis – muscle biopsy with immunohistochemistry (used less often now that DNA testing is available).

Cardiac and pulmonary assessment

• Baseline echocardiogram and ECG at diagnosis; repeat annually.
• Pulmonary function tests (spirometry) beginning in early school years.

Additional imaging

• MRI of lower limbs can quantify fatty infiltration and guide physiotherapy.

Treatment Options

There is no cure, but multidisciplinary care can slow progression, improve quality of life, and extend survival.

Pharmacologic therapies

• Corticosteroids (prednisone or deflazacort) – first‑line; improve muscle strength and delay loss of ambulation by 2‑3 years. Long‑term side effects include weight gain, hypertension, and bone loss; bone‑protecting agents (vitamin D, calcium) are recommended.
• Exon‑skipping drugs – eteplirsen (exon 51), golodirsen (exon 53), viltolarsen (exon 53), and casimersen (exon 45). These are FDA‑approved for subsets of DMD patients with amenable mutations; they produce a truncated but functional dystrophin.
• Nonsense‑mutation read‑through – ataluren (for patients with stop‑codon mutations).
• Cardiac medications – ACE inhibitors or ARBs, beta‑blockers, and mineralocorticoid receptor antagonists to treat cardiomyopathy.
• Respiratory support – nocturnal non‑invasive ventilation (BiPAP) when forced vital capacity falls <30 %.

Procedural interventions

• Scoliosis surgery – spinal fusion when curvature >40° and before severe pulmonary compromise.
• Orthopedic procedures – tendon lengthening for contractures.
• Ventilatory support – daytime mechanical ventilation or tracheostomy in advanced respiratory failure.

Therapeutic & lifestyle measures

• Physical therapy – daily stretching, low‑impact strengthening, and gait training.
• Occupational therapy – adaptive equipment for daily living (wheelchairs, splints, communication devices).
• Nutrition – high‑protein diet, caloric monitoring, and supplementation with vitamin D & calcium.
• Assistive technology – power wheelchairs, standing frames, and environmental controls.

Living with X‑linked Dystrophinopathy (Duchenne/Becker Muscular Dystrophy)

Managing day‑to‑day life involves a team approach (neurologist, cardiologist, pulmonologist, physiotherapist, genetic counselor, and psychosocial support).

Practical tips

• Maintain a regular stretching schedule – 15‑30 minutes each day to prevent contractures.
• Stay active within limits – swimming, stationary cycling, or assisted walking conserve muscle tone without over‑exertion.
• Monitor weight – rapid gain stresses weakened joints and heart.
• Schedule routine cardiac and pulmonary evaluations – early detection of cardiomyopathy or respiratory decline is vital.
• Vaccinations – annual flu shot and pneumococcal vaccines to reduce respiratory infections.
• Plan for transitions – school accommodations (504 plan), vocational counseling, and adult‑care services.
• Psychosocial support – counseling, support groups (e.g., Parent Project Muscular Dystrophy), and mental‑health care for anxiety/depression.

Family & carrier considerations

Genetic counseling is recommended for all families. Female carriers should undergo cardiac screening (EKG, echo) every 3‑5 years, as up to 30 % develop cardiomyopathy later in life [3].

Prevention

Because the mutation is inherited, prevention focuses on informed reproductive choices:

• Carrier testing for at‑risk females (sisters, mothers, maternal aunt).
• Pre‑implantation genetic diagnosis (PGD) with IVF to select embryos without the pathogenic DMD variant.
• Prenatal testing – chorionic villus sampling (CVS) or amniocentesis for families with a known mutation.
• Family planning counseling – discussion of options such as sperm/egg donation or adoption.

There is no lifestyle modification that can prevent the disorder in a genetically predisposed individual.

Complications

If untreated or inadequately managed, dystrophinopathy can lead to serious, life‑threatening problems:

• Cardiomyopathy – progressive heart failure; leading cause of death in DMD after the second decade.
• Respiratory failure – due to weakening of diaphragm and intercostal muscles; infections can precipitate acute decompensation.
• Scoliosis – excessive curvature compromises pulmonary function.
• Bone fractures – from low bone mineral density.
• Venous thromboembolism – reduced mobility increases risk.
• Psychosocial issues – isolation, depression, and academic challenges.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Duchenne muscular dystrophy. https://www.mayoclinic.org.
2. Cleveland Clinic. Becker muscular dystrophy. https://my.clevelandclinic.org.
3. NIH Office of Rare Diseases Research. Dystrophinopathies. https://rarediseases.info.nih.gov.
4. American Heart Association. Cardiomyopathy in muscular dystrophy. https://www.heart.org.
5. U.S. Food & Drug Administration. FDA approves eteplirsen for DMD. https://www.fda.gov.